Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03066063 · ClinicalTrials.gov registry record

A New Approach to Vision Therapy Based on Naturalistic 3-D Computer Gaming

A clinical trial of Amblyopia and Ocular Motility Disorders, sponsored by Barron Associates.

Completed
Registry status
92
Enrollment target
1
Study location

NCT03066063 is a study of Amblyopia and Ocular Motility Disorders that has completed, run by Barron Associates. The registered enrollment target is 92 participants, below the 162-participant average among 24 other Amblyopia trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03066063, a study of Amblyopia and Ocular Motility Disorders, has completed, sponsored by Barron Associates.

COMPLETED
Registry status
92 participants
Enrollment target
1
Study location

Study Summary

The research team will execute two concurrent studies within a common framework. The first will compare iCare to standard of care occlusion therapy (patching) for amblyopia in patients ages 4 to 18 (inclusive). The second will compare iCare to a standard of care for home-based CI therapy (pencil pushups) for convergence insufficiency patients ages 8 to 18 (inclusive). In the context of this study, the term iCare refers to either the amblyopia or CI video game module as appropriate for the respective study group.

Interventions

  • DEVICE iCare
  • BEHAVIORAL Amblyopia standard of Care
  • BEHAVIORAL CI standard of Care

Study Locations (1)

Tennessee

  • Southern College of Optometry - Memphis

Trial Details

FieldValue
Enrollment Target 92 participants
Start Date 2019-05-07
Est. Completion 2022-02-28

Sponsor

Barron Associates

10 total trials

What the Registry Record Tells You About NCT03066063

The ClinicalTrials.gov registry entry for NCT03066063 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 162-participant average among 24 other Amblyopia trials with a reported enrollment target (43% lower). The listed sponsor is Barron Associates, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Amblyopia appearing as the primary indexed condition, and to 3 interventions - of which iCare is the first listed.

NCT03066063 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT03066063 about?

NCT03066063 is a clinical study titled "A New Approach to Vision Therapy Based on Naturalistic 3-D Computer Gaming". The research team will execute two concurrent studies within a common framework. The first will compare iCare to standard of care occlusion therapy (patching) for amblyopia in patients ages 4 to 18 (inclusive). The second will compare iCare to a standard of care for home-based CI therapy (pencil pus...

What is the current status of trial NCT03066063?

This trial is currently completed. The enrollment target is 92 participants. The study started on 2019-05-07. Estimated completion is 2022-02-28.

What conditions does trial NCT03066063 study?

This clinical trial studies the following conditions: Amblyopia, Ocular Motility Disorders.

What interventions are being tested in trial NCT03066063?

The interventions under investigation include: iCare (DEVICE), Amblyopia standard of Care (BEHAVIORAL), CI standard of Care (BEHAVIORAL).

Who is sponsoring clinical trial NCT03066063?

This trial is sponsored by Barron Associates, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03066063 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Amblyopia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.